Profile

VeriLuce Therapeutics is a biotech company focusing on the development of novel small molecules targeting in dual antagonistic mode chemokine receptors in the immune-tumor-micro-environment.   The objective is to modulate the immune tumor micro-environment to block the communication between tumor cells and immune/network cells that support tumor cells growth to ultimately block tumor cell expansion and metastasis.

VeriLuce Therapeutics Inc. logo

Website

verilucetherapeutics.com

Contact


Event details

Date: December 1 - 5, 2025

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

13 in total